Evidence map›Paper›PMID 32397023›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2019

[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].

P Huang, S Chen, X Yang, Y Y Lei, X Y Xu, Y X Liu, Y H Guo, Y Pan, X H Wang, H L Zhang and 2 more

Open access · greenAbstract read
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Influence ofCancers · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

P HuangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
S ChenTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
X YangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
Y Y LeiTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
X Y XuTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
Y X LiuTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
Y H GuoTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
Y PanTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
X H WangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
H L ZhangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
K FuDepartment of Pathology and Microbiology, UNMC, Omaha, USA.
B MengTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
Tianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HumansLymphoma, Large B-Cell, DiffusePrognosisProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycTumor Suppressor Protein p53BCL2 protein, humanMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycTP53 protein, humanTumor Suppressor Protein p53BCL2Diffuse large B-cell lymphomaDouble-expression lymphomaP53Prognosis

Identifiers

PMID32397023
PMCPMC7364905
OpenAlexW3026287483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.